The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1?34)]
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602 · cited 2×
“6% observed with 4 years of sequential therapy, approximately 2 years of hPTH (1–34) and 2 years of bisphosphonate, exceeds the published experience for any of these drugs alone [1, 2, 12, 13, 14, 15, 16], Fig.”
BackgroundResultHeaney, R. P. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091003 · Cited by 286 · cited 1×
“Thus, the primary actions of bisphosphonates to reduce bone turnover [21], in turn, reducing the remodeling space, increasing bone volume, as well as increasing the mineral content of the matrix [22], are enhanced in the setting of both the higher bone turnover and larger remodeling space of 18 versus 30 months of PTH…”
Background
Cited by
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
“35,47,48”
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Self-citationEbeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332
Metadata
- Authors
- Kurland, E. S., Heller, S. L., Diamond, B., McMahon, D. J., Cosman, F., & Bilezikian, J. P.
- Venue
- Osteoporosis International
- Published
- 2004-06-03
- Volume
- 15
- Issue
- 12
- Pages
- 992-997
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2080818296
- Cited by
- 173
- References
- 3
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1?34)]. https://app.cochat.ai/papers/10.1007/s00198-004-1636-z
- The paper
- Kurland, E. S., Heller, S. L., Diamond, B., McMahon, D. J., Cosman, F., & Bilezikian, J. P. (2004). The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1?34)]. Osteoporosis International. https://doi.org/10.1007/s00198-004-1636-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.